Azenta, Inc. (AZTA) Latest Company News

Sep 17, 2026, 19:52 UTC
Azenta, Inc. granted Senior Vice President, General Counsel and Corporate Secretary Ephraim Starr a retention award of restricted stock units valued at $500,000 effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. granted Executive Vice President and Chief Financial Officer Lawrence Lin a retention award of restricted stock units valued at $1,000,000 effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. appointed Robyn C. Davis to its Nominating and Governance Committee effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. appointed Frank E. Casal to its Nominating and Governance Committee effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. named William L. Cornog as Chair of its Nominating and Governance Committee effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. appointed Dr. Martin D. Madaus to its Nominating and Governance Committee effective September 14, 2026.
Sep 17, 2026, 19:52 UTC
Azenta, Inc. appointed Dr. Martin D. Madaus as Interim President and Chief Executive Officer effective September 14, 2026.
Sep 4, 2026, 12:00 UTC
Azenta, Inc. received full repayment, prior to maturity, of a $35 million secured vendor loan related to the sale of B Medical Systems S.
Source:
- prnewswire.com
- seekingalpha.com
Aug 24, 2026, 00:00 UTC
John P. Marotta resigned as President and Chief Executive Officer and member of the Board of Directors of Azenta, Inc., effective August 22, 2026.
Source:
- prnewswire.com
- s.kabutan.jp
Aug 4, 2026, 20:30 UTC
Azenta, Inc. reported its financial results for the third quarter of fiscal 2026, which ended on June 30, 2026.
Source:
Jul 8, 2026, 12:00 UTC
Azenta completed the sale of its B Medical Systems business to Thelema S.
Source:
- prnewswire.com
Jul 8, 2026, 00:00 UTC
Azenta Inc. completed the sale of its subsidiary B Medical Systems S.à r.l. to Thelema S.à r.l. for a total purchase price of $63 million on July 1, 2026.

AZTA

Azenta, Inc. granted Senior Vice President, General Counsel and Corporate Secretary Ephraim Starr a retention award of restricted stock units valued at $500,000 effective September 14, 2026.

Azenta, Inc. granted Executive Vice President and Chief Financial Officer Lawrence Lin a retention award of restricted stock units valued at $1,000,000 effective September 14, 2026.

Azenta, Inc. appointed Robyn C. Davis to its Nominating and Governance Committee effective September 14, 2026.

Azenta, Inc. appointed Frank E. Casal to its Nominating and Governance Committee effective September 14, 2026.

Azenta, Inc. named William L. Cornog as Chair of its Nominating and Governance Committee effective September 14, 2026.

Azenta, Inc. appointed Dr. Martin D. Madaus to its Nominating and Governance Committee effective September 14, 2026.

Azenta, Inc. appointed Dr. Martin D. Madaus as Interim President and Chief Executive Officer effective September 14, 2026.

Azenta, Inc. received full repayment, prior to maturity, of a $35 million secured vendor loan related to the sale of B Medical Systems S.

John P. Marotta resigned as President and Chief Executive Officer and member of the Board of Directors of Azenta, Inc., effective August 22, 2026.

Azenta, Inc. reported its financial results for the third quarter of fiscal 2026, which ended on June 30, 2026.

Azenta completed the sale of its B Medical Systems business to Thelema S.

Azenta Inc. completed the sale of its subsidiary B Medical Systems S.à r.l. to Thelema S.à r.l. for a total purchase price of $63 million on July 1, 2026.